Actively Recruiting
An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma
Led by Princess Maxima Center for Pediatric Oncology · Updated on 2026-02-10
22
Participants Needed
1
Research Sites
77 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a non-randomized, open label phase Ib/II dose-escalation and expansion study designed to define the recommended dose of anti-GD2-800CW in pediatric neuroblastoma patients. The aim of this imaging study is to determine a safe and effective dose of anti-GD2-800CW for intra-operative detection of neuroblastoma using NIR fluorescence.
CONDITIONS
Official Title
An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with neuroblastoma confirmed by pathology who will undergo surgery as standard care
- Patients aged older than 1 year and not older than 18 years
- Written informed consent from patients and/or parents or legal guardians as required by law
You will not qualify if you...
- Previous treatment with Dinutuximab-beta alone or with chemotherapy
- Pregnancy or positive pregnancy test in females of childbearing potential
- Breastfeeding
- Sexually active participants unwilling to use highly effective contraception during and 6 months after the study
- Patients previously treated with chimeric antibodies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Prinses Maxima Centrum
Utrecht, Netherlands
Actively Recruiting
Research Team
M
Marieke Kietselaer
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here